MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice

Brittany A Riggle,Sanhita Sinharay,William Schreiber-Stainthorp,Jeeva P Munasinghe,Dragan Maric,Eva Prchalova,Barbara S Slusher,Jonathan D Powell,Louis H Miller,Susan K Pierce,Dima A Hammoud,Brittany A. Riggle,Jeeva P. Munasinghe,Barbara S. Slusher,Jonathan D. Powell,Louis H. Miller,Susan K. Pierce,Dima A. Hammoud
DOI: https://doi.org/10.1073/pnas.1812909115
IF: 11.1
2018-12-04
Proceedings of the National Academy of Sciences
Abstract:Significance Cerebral malaria (CM) is the deadliest complication of Plasmodium falciparum infection, resulting in a 15 to 25% mortality rate in African children despite antimalarial chemotherapy. Tragically, nearly a fourth of pediatric CM survivors suffer long-term neurological sequelae. There is an urgent public health and humanitarian need for therapies for CM. In a mouse model of CM, we used magnetic resonance imaging (MRI) to monitor infected mice longitudinally as CM progressed and noninvasively demonstrate that the edema and blood–brain barrier dysfunction, which ultimately result in death, are rapidly reversed by treatment with the glutamine antagonist JHU-083. The similarities between CM MRI shown in mice and those reported in children and adults suggest that glutamine antagonists may be effective CM therapies.
multidisciplinary sciences
What problem does this paper attempt to address?